BioCardia Inc
NASDAQ:BCDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BioCardia Inc
NASDAQ:BCDA
|
US |
|
Parsvnath Developers Ltd
NSE:PARSVNATH
|
IN |
|
K
|
Kovilpatti Lakshmi Roller Flour Mills Ltd
BSE:507598
|
IN |
|
Hexagon AB
OTC:HXGBF
|
SE |
|
Opsens Inc
TSX:OPS
|
CA |
|
Umicore SA
XBRU:UMI
|
BE |
|
Brain Scientific Inc
OTC:BRSF
|
US |
|
Sok Marketler Ticaret AS
IST:SOKM.E
|
TR |
|
W
|
Whirlpool SA
BOVESPA:WHRL3
|
BR |
|
Stantec Inc
TSX:STN
|
CA |
|
GOME Retail Holdings Ltd
HKEX:493
|
CN |
BioCardia Inc
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in Sunnyvale, California and currently employs 28 full-time employees. The company is focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Its lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow-derived cell therapy for treatment in two clinical indications, such as ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. Its second therapeutic platform is an investigational bone marrow derived allogeneic off-the shelf Neurokinin-1 Receptor Positive mesenchymal stem cell (MSC) therapy for the treatment of cardiac and pulmonary disease. The company has three enabling device product lines: the CardiAMP cell processing system, the Helix biotherapeutic delivery system (Helix), and the Morph vascular access product line (Morph). The company is advancing therapeutic candidates for heart failure, chronic myocardial infarction, and acute respiratory distress syndrome.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in Sunnyvale, California and currently employs 28 full-time employees. The company is focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Its lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow-derived cell therapy for treatment in two clinical indications, such as ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. Its second therapeutic platform is an investigational bone marrow derived allogeneic off-the shelf Neurokinin-1 Receptor Positive mesenchymal stem cell (MSC) therapy for the treatment of cardiac and pulmonary disease. The company has three enabling device product lines: the CardiAMP cell processing system, the Helix biotherapeutic delivery system (Helix), and the Morph vascular access product line (Morph). The company is advancing therapeutic candidates for heart failure, chronic myocardial infarction, and acute respiratory distress syndrome.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
